Stevanato Group stock reaction and recent context

Stevanato Group (STVN) shares recently closed at US$17.08, with the stock down about 5% over the past month but up roughly 11% over the past 3 months.

Zooming out, the stock’s 11.27% 90 day share price return contrasts with a year to date share price decline of 17.01%, and a 1 year total shareholder return decline of 26.99%. This suggests that recent momentum is improving after a weaker longer term stretch.

If Stevanato Group’s recent swings have you rethinking your watchlist, this could be a good moment to hunt for other ideas through our 40 healthcare AI stocks

With Stevanato Group reporting €1,203.26m in revenue and €141.35m in net income, yet the stock trading at US$17.08 and carrying a low value score of 2, should you see mispricing here, or are markets already factoring in future growth?

Most Popular Narrative: 31.2% Undervalued

With Stevanato Group last closing at $17.08 against a narrative fair value of $24.81, the most widely followed view sees meaningful upside potential from here.

Secular shifts toward self-administration and personalized medicine are accelerating demand for specialized, integrated drug delivery devices (e.g., auto-injectors, pen injectors, and dual/chamber syringes). These are areas where Stevanato is expanding capacity and capability, suggesting greater future revenue mix from higher-margin solutions and sustained margin expansion.

Curious what kind of revenue mix shift and margin profile would need to play out to justify that higher fair value estimate at a premium P/E? The narrative leans heavily on compound earnings growth, fatter net margins, and a future valuation multiple that assumes investors will keep paying up for this earnings stream.

Result: Fair Value of $24.81 (UNDERVALUED)

However, this hinges on capital projects and the Engineering segment improving as planned, as well as on concentrated biopharma customers not pulling back or shifting volumes elsewhere.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another angle on valuation

While the narrative fair value of $24.81 frames Stevanato Group as 31.2% undervalued, the SWS DCF model tells a very different story, with an estimated future cash flow value of $8.41, which puts the stock as expensive on that measure. Which lens do you trust more when cash flows and narratives disagree?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Stevanato Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution has you on the fence, take a closer look now and decide where you stand by reviewing the 3 key rewards.

Ready for more investment ideas?

Do not stop with one stock. If you skip the wider opportunity set, you risk missing companies that could fit your goals and risk comfort far better.

• Target quality at a discount by scanning the 44 high quality undervalued stocks and see which stocks currently combine strong fundamentals with lower prices.
• Prioritise resilience by checking the 71 resilient stocks with low risk scores to focus on companies with steadier risk profiles.
• Spot future standouts early by reviewing the screener containing 20 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.